Resverlogix Corp. (TSE:RVX – Get Free Report) shares reached a new 52-week low during trading on Friday . The company traded as low as C$0.05 and last traded at C$0.05, with a volume of 216634 shares changing hands. The stock had previously closed at C$0.05.
Resverlogix Price Performance
The company has a 50-day moving average of C$0.05 and a two-hundred day moving average of C$0.06. The stock has a market capitalization of C$8.91 million, a PE ratio of -2.23 and a beta of 0.71. The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Read More
- Five stocks we like better than Resverlogix
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- 3 Monster Growth Stocks to Buy Now
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
